EnVVeno Medical Q2 2025 Financial Report and Corporate Update

enVVeno Medical Corporation reported its financial results for Q2 2025, revealing a cash burn of $3.8 million, aligning with the predicted range of $4-5 million. The company holds $35.1 million in cash and investments, ensuring operational funding through Q3 2026 at the current burn rate. Plans for the phased launch of VenoValve® depend on an FDA decision anticipated in the second half of 2025.

In clinical advancements, the VenoValve® is undergoing FDA review, while enVVe® completed the final wave for a pre-clinical study, aiming for an IDE submission by late 2025. The company aims to lead in severe deep venous disease treatment, with CEO Robert Berman emphasizing strategic progress. enVVeno experienced an increased net loss of $6.7 million for the quarter, primarily due to higher operating costs.